Announcement

Collapse
No announcement yet.

Genetech presenting new data on Ocrelizumab at AAN meeting

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Genetech presenting new data on Ocrelizumab at AAN meeting

    Genentech to Present New Data at AAN Showing Superior Efficacy of Investigational Medicine Ocrelizumab Versus Comparators on Disease Activity and Progression in Two Forms of Multiple Sclerosis

    New analyses showing superior efficacy of ocrelizumab across clinical and subclinical outcomes compared with interferon beta- 1a (Rebif®) in people with relapsing multiple sclerosis (MS) and compared with placebo in primary progressive MS will be presented

    April 12, 2016 01:17 PM Eastern Daylight Time
    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)

    Genentech, a member of the Roche group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from three Phase III studies of the investigational medicine OCREVUS™ (ocrelizumab) will be presented during the 68th American Academy of Neurology (AAN) annual meeting from April 15-21 in Vancouver, Canada.

    In addition, results of a novel endpoint, No Evidence of Disease Activity (NEDA) will be presented from the Phase III studies in relapsing MS at the Clinical Trials Plenary Session on Wednesday, April 20. NEDA is a composite of key measures of disease activity that assesses level of disease control. Patients are considered to have achieved NEDA if they have no relapses, no disability progression and no new or enlarging MRI lesions over a specified time interval, for example, two years of a clinical trial.

    “The data being presented at AAN show that ocrelizumab significantly reduced disability progression and brain tissue damage in both relapsing and primary progressive forms of MS,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “The analyses demonstrate ocrelizumab’s consistent effect across important measures of disease activity and provide further insights into the clinical effect of ocrelizumab in people with MS.”

    Presentation Thursday, April 21: Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study

    http://www.businesswire.com/news/hom...erior-Efficacy

    http://multiplesclerosisnewstoday.co...nnual-meeting/
    Last edited by Kimba22; 04-19-2016, 09:52 PM.
    Kimba

    “When you change the way you look at things, the things you look at change.” ― Max Planck
Working...
X